Related references
Note: Only part of the references are listed.CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC).
Alan P. Venook et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial)
A. Stahler et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
A. Rowland et al.
BRITISH JOURNAL OF CANCER (2015)
First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis
Filippo Pietrantonio et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer
C. Bokemeyer et al.
EUROPEAN JOURNAL OF CANCER (2015)
Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer
Jean-Yves Douillard et al.
EUROPEAN JOURNAL OF CANCER (2015)
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
O-0030INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306)
V. Heinemann et al.
ANNALS OF ONCOLOGY (2014)
Final results from a randomized phase 3 study of FOLFIRI +/- panitumumab for second-line treatment of metastatic colorectal cancer
M. Peeters et al.
ANNALS OF ONCOLOGY (2014)
Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer
D. J. Jonker et al.
BRITISH JOURNAL OF CANCER (2014)
Progression-Free Survival Remains Poor Over Sequential Lines of Systemic Therapy in Patients With BRAF-Mutated Colorectal Cancer
Van Morris et al.
CLINICAL COLORECTAL CANCER (2014)
Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC)
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): New results from the CRYSTAL trial
Fortunato Ciardiello et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
Lee S. Schwartzberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan
Fotios Loupakis et al.
TARGETED ONCOLOGY (2014)
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
George Pentheroudakis et al.
BMC CANCER (2013)
Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer
Marc Peeters et al.
CLINICAL CANCER RESEARCH (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study
Josef Thaler et al.
BMC CANCER (2012)
BRAF Mutation Status and Survival after Colorectal Cancer Diagnosis According to Patient and Tumor Characteristics
Amanda I. Phipps et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2012)
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
Claus-Henning Koehne et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2012)
Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts
Heikki Joensuu et al.
LANCET ONCOLOGY (2012)
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
C. Bokemeyer et al.
ANNALS OF ONCOLOGY (2011)
Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
L. Bennett et al.
BRITISH JOURNAL OF CANCER (2011)
Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
J. B. Baker et al.
BRITISH JOURNAL OF CANCER (2011)
The Efficacy and Safety of Panitumumab Administered Concomitantly With FOLFIRI or Irinotecan in Second-Line Therapy for Metastatic Colorectal Cancer: The Secondary Analysis From STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS Status
Edith P. Mitchell et al.
CLINICAL COLORECTAL CANCER (2011)
An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer
Allen L. Cohn et al.
CLINICAL COLORECTAL CANCER (2011)
Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer
Mario E. Lacouture et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer
S. Sehdev et al.
CURRENT ONCOLOGY (2009)
Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab
Bart Jacobs et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: Survey results
Susan L. Boone et al.
ONCOLOGY (2007)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
